Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding During Suppressive Antiretroviral Therapy
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Long-term consequences of human immunodeficiency virus (HIV) are likely the result of persistent inflammation and immune dysfunction of which cytomegalovirus (CMV) is a known contributor. We leveraged 2 AIDS Clinical Trials Group clinical trials exploring the effects of immune modulators (ruxolitinib and sirolimus) on inflammation in people with HIV on antiretroviral therapy to determine whether these interventions affected CMV shedding at various mucosal sites. Analyzing 635 mucosal samples collected, we found no significant difference in CMV levels across study arms or time points. Men had more CMV shedding than women. We did confirm an association between higher CMV DNA and immune markers associated with HIV persistence and HIV-associated mortality rates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 228(2023), 1 vom: 28. Juni, Seite 64-69 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hastie, Elizabeth [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CMV |
|---|
| Anmerkungen: |
Date Completed 30.06.2023 Date Revised 11.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353877050 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353877050 | ||
| 003 | DE-627 | ||
| 005 | 20240411232031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM353877050 | ||
| 035 | |a (NLM)36881933 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hastie, Elizabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding During Suppressive Antiretroviral Therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2023 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Long-term consequences of human immunodeficiency virus (HIV) are likely the result of persistent inflammation and immune dysfunction of which cytomegalovirus (CMV) is a known contributor. We leveraged 2 AIDS Clinical Trials Group clinical trials exploring the effects of immune modulators (ruxolitinib and sirolimus) on inflammation in people with HIV on antiretroviral therapy to determine whether these interventions affected CMV shedding at various mucosal sites. Analyzing 635 mucosal samples collected, we found no significant difference in CMV levels across study arms or time points. Men had more CMV shedding than women. We did confirm an association between higher CMV DNA and immune markers associated with HIV persistence and HIV-associated mortality rates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a CMV | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a immune modulators | |
| 650 | 4 | |a ruxolitinib | |
| 650 | 4 | |a sirolimus | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Moser, Carlee |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Lennox, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Hsue, Priscilla Y |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Ronald J |e verfasserin |4 aut | |
| 700 | 1 | |a Deeks, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Meneses, Milenka V |e verfasserin |4 aut | |
| 700 | 1 | |a Lederman, Michael M |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Henrich, Timothy J |e verfasserin |4 aut | |
| 700 | 1 | |a Marconi, Vincent C |e verfasserin |4 aut | |
| 700 | 1 | |a Gianella, Sara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 228(2023), 1 vom: 28. Juni, Seite 64-69 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:1 |g day:28 |g month:06 |g pages:64-69 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e 1 |b 28 |c 06 |h 64-69 | ||